Objective: Extracorporeal circulation procedures have been shown to induce complement and leukocyte activation, release of endotoxin and in¯ammatory mediators, including cytokines, nitric oxide, oxygen free radicals, and platelet activating factors. The contact between the blood and the various arti®cial surfaces of the extracorporeal system results in an unspeci®c post-perfusion syndrome. For diminishing these negative side effects several coating-techniques have been developed to create devices with improved hemocompatibility. Methods: This review deals with the current knowledge of heparin-coated and otherwise surface-modi®ed perfusion systems. The pathway how heparincoated surfaces work is discussed and techniques for surface-coatings, both clinically introduced as well as newly developed are presented. Results: Numerous clinical studies compared heparin-coated versus non-coated circuits. Heparin-bonded devices showed lessened humoral and cellular activation, in particular a reduced complement activation with a reduced in¯ammatory post-perfusion syndrome. Also platelet protection and more favorable post-operative lung function are of particular note. Recent clinical trials demonstrated shortened hospital stays, less drainage bleeding, and reduced cerebral complications using heparin-coated oxygenation systems. The diminished expression of the leukocyte adhesion molecules CD 11b/c in CBAS devices points to a decreased activation of neutrophils. In addition, one research group found a reduced production of oxygen radicals. Heparin-bonding minimizes oxygenator failure by a signi®cant reduced pressure gradient across the oxygenator, probably caused by decreased ®brin and platelet deposition at the hollow ®ber surfaces. A meta analysis examined the impact of heparin-bonded systems on clinical outcomes and resulting costs. Using heparin-bonded circuits led to total cost savings from US $ 1000 to 3000. Several authors demonstrated reduced blood loss and better clinical outcome by reduction of systemic heparinization and the employment of heparin-coated devices. Conclusion: Above and beyond the long-term applications, routine heart operations have also markedly begun to utilize heparin-coated devices. This trend will assuredly continue in the coming years and is an important step toward higher hemocompatibility of blood-contacting surfaces in the ECC device. Heparin-coatings are merely the beginning of improved hemocompatibility for all materials that come into contact with human blood or tissues. Intelligent materials with almost completely physiological surfaces will be at the surgeon's disposal within the next few years. q
Introduction
In 1996, 765 000 heart operations world-wide were performed with the assistance of extracorporeal circulation (ECC), whereby approximately half (380 000) were done in the USA [1] . With respect to the age and physical condition of patients, all surgeons have found a shift toward older, frailer adults on one hand and younger children (up to 50% infants, half of them new-borns) on the other. The results of this displacement could be altered to the bene®t of the patients undergoing open heart surgery by continual improvement of the operative techniques, as well as the perioperative supervision and the mechanical circulatory support systems. For the last option, the optimization of the surfaces of the ECC devices becomes of increased importance, both during the operation (e.g. heart-lung machine, partial left heart ventricular bypass) and after (short term: external uni-or biventricular pump systems, such as the Berlin heart; long term: internal ventricular pumps, such as TCI or Novacor). Next to the technical perfection of all these systems, it is also particularly important to consider the surfaces presented to the in general extracorporeally circulating blood.
Since its ®rst use 40 years ago, extracorporeal circulation (ECC) during open heart surgery has developed around the globe into a routine procedure. Nevertheless, the insuf®cient hemocompatibility of the materials used for ECC devices European Journal of Cardio-thoracic Surgery 16 (1999) 342±350 still remains a problem. The contact between the blood and the various arti®cial surfaces of the extracorporeal system leads postoperatively to the so-called post-perfusion syndrome (or post-pump syndrome), which can escalate in severe cases into the systemic in¯ammatory response syndrome (SIRS) [2] , acute lung failure (ARDS: adult respiratory distress syndrome) [3] , sepsis, or even multiorgan failure (MOF) [4] . The causes of these syndromes are multi-factorial: mechanical and chemotactic activation and membrane-damage of the corpuscular components of the blood, dysfunction of the cellular immune regulation, activation of the hemostaseologic activation cascades, connected to one another through various feedback mechanisms, i.e. the contact phase (Factor XII-kallikrein-kinin system), intrinsic and extrinsic coagulation, ®brinolysis, and complement, as well as their cell-and tissue-damaging release products, such as free oxygen radicals, proteinases, nitric oxide, cytokines, endotoxins, etc. [4] .
Components and effects of the extracorporeal devices
The medical devices that ®nd either intra-or extracorporeal application embrace a wide spectrum of synthetic materials: polyethylene, polypropylene, polyvinylchloride (PVC), polyester, polystyrene, polyurethane, silicone, polysulphone, polyamide, polytetra¯uoroethylene, their derivatives, etc. Although these products possess excellent physical properties, they were nonetheless developed primarily for industrial use and only later found their way into biomedicine. Thus, all these synthetic materials display more or less the same disadvantage: an incompatibility with blood and tissues. Through contact with the blood, this incompatibility can provoke a pathophysiological response from the organism, similar to that of traumatic shock. As is well known, in adult patients undergoing a bypass grafting procedure the total blood volume comes into contact with about 3 m 2 of these non-physiological surfaces for one to several hours. This extensive contact causes a massive activation of the humoral and cellular defense systems against the supposed`invader', and with that, the human body boosts the various cascade reactions into motion.
Insofar a reduction of these pathophysiological defensive mechanisms induced by blood/material interactions has top priority. Two further fundamentally different approaches are reasonable in principal: (A), reduction of the surfaceinduced activation mechanisms by improving the hemocompatibility of the device materials or (B), pharmacological inhibition of the key enzymes responsible for the consecutive activation of the cascade reactions (e.g. aprotinin, tranexamic acid, e-aminocapron acid, C1-esterase inhibitor, antioxidants, free radical scavengers, immunoglobulins, etc.) This review will not further debate point B. However, it should be noted that several other authors have suggested a combination of both procedures A and B, such as heparincoated oxygenation systems and aprotinin application [5, 6] .
Heparin-coating
It was recognized relatively early that an improvement in the hemocompatibility of the materials used in biomedical applications could signi®cantly contribute to reduce extreme reactions. The attempt to coat the arti®cial surfaces with heparin, an anticoagulant that imitates the antithrombogenic effects of heparansulfate at the endothelium, illustrates the ®rst step toward attaining better hemocompatibility [7] . Through the homogeneous lining of the extracorporeal system, from canula to canula, the blood should encounter a uniform surface area. Gott and coworkers in 1963 [8] had previously reported on heparin-coating of synthetic materials, which had been pre-treated with colloidal graphite. Consequently, the following years saw work on an improved binding technique, in which the negatively-charged heparin molecules were bound to the solid, positively-charged ammonium ions. Larm and others [9] presented a heparincoating method in 1983, which is still the most stable and most effective for long-term use. Their method involving covalent binding by the technique of end-point immobilization, did not adversely affect the heparin molecule's active sequence and thus produced an extremely bioactive surface structure (Fig. 1) .
As the ®rst heparin-coated oxygenators become available in the last half of the 1980s, many research groups examined the oxygenators' hemocompatibility in in-vitro systems, animal models, and later, in patient studies (see reviews from Gravlee, 1994 [10] , Janvier, 1996 [11] , and Hsu, 1997 [12] ). The data published thus far are indeed relatively inhomogeneous; nonetheless, it can be assumed that heparin-coated oxygenators can cause a reduction of the following cascade reactions and/or symptoms: activation of the contact phase, complement system activation, alteration of granulocytes, in¯ammation, and pulmonary complications, activation of platelets, disturbance of homeostasis, loss of blood, and cerebral damage (literature overview see Tables 1 and 2 ).
Oxygenator failure
A dreaded complication during ECC is oxygenator failure by development of an abnormal pressure gradient (APG) across the oxygenator. This phenomenon is presumably caused by increased ®brin and platelet deposition at the oxygenators' surfaces, resulting in a diminished space for the blood¯ow particularly between the hollow-®bers. Wahba et al. [13] demonstrated in a study with 1959 patients that APG can be avoided by using heparin-coated devices.
Reduced anticoagulation protocol
Whether or not a reduction of systemic heparinization is possible through the employment of heparin-coated extracorporeal circulation components is still an issue of controversy [14±16]. By using a reduced heparin-dose, several authors demonstrated better homeostasis [17±21] and better clinical outcome [22±26] . Moreover, one must consider that the coagulation during ECC can occur not only on account of the non-physiological surfaces (intrinsic pathway) but also as a result of the surgical intervention (intrinsic and extrinsic (tissue-factor) pathway) [27] .
Cost-bene®t analysis
The industrial heparin-coating procedure of CPB-devices is still costly and therefore most companies have to compensate this by charging higher prices. Very rare data are available about cost ef®ciency of heparin-coated circuits. Mahoney [26] very recently published a meta-analysis to examine the impact of heparin-bonded systems on clinical outcomes and resulting costs. He found total cost savings of US$ 3231 by using covalently bonded circuits versus US$ 1068 with ionically coatings. However, this numbers differ extremely between the hospitals included in the analysis.
How heparin-coating works
Early on, many authors supported the hypothesis that the reduced thrombogenicity of the heparin-coated surfaces was attributable to the catalytic effects on antithrombin III and the accompanying formation of thrombin complexes. However, more recent knowledge shows that this hypothesis can no longer be maintained. Rather, the advantage of heparin-coats lies much more in the reduced, or selective, adhesion of plasma proteins, which in turn leads to a faster formation of a blood-friendly secondary super®cial membrane on the one hand, and on the other hand prevents a further denaturation and hence activation of the adhered proteins and blood cells. Several research groups, in particular those of Vroman and Brash, were able to prove that plasma proteins on the arti®cial surface, such as F XII, ®brinogen, vitronektin, HMWK, and others, provide a signi®cant criterion for further thrombogenicity [28] . Solidphase bound ®brinogen leads to a strong adhesion of the platelets by their respective glycoprotein receptors, followed by platelet aggregation, and release of procoagulant contents like platelet factor 4. Additionally, PMNleukocytes show an upregulation of the adhesion molecules CD 11b and CD 18 with increased sticking to the surface, release of elastase and superoxide generation; i.e. beginning of the in¯ammatory response [29, 30] . Didisheim and Watson [31] put forth the hypothesis that the thrombogenicity of arti®cial surfaces depends mainly on the extent to which the activation and inhibition of platelet adhesion and aggregation ± a process of permanent equilibrium reaction at the natural endothelium ± can be simulated. This equilibrium reaction underlies both plasmatic as well as cellular auto-regulation and reverse feedback mechanisms. As soon as the blood comes in contact with the negatively-charged surface, factor XII, which occurs in an inactive complex with prekallikrein, F XI and HMWK, splits off into a-and b-factor XIIa fragments. These fragments then initiate the entire contact phase activation system. b-factor XIIa converts the zymogen prekallikrein into its active form, kallikrein, which splits the vasodilator bradykinin from HMWK [32] . Moreover, kallikrein possesses pro-®brinoly-tic powers via plasminogen activation and also stimulates the chemotactic activity of neutrophilic granulocytes [32, 33] . Relationships between the initial phases of classic complement activation (C1) and the contact phase system as well as the key enzyme for ®brinolysis (plasmin) have already been described in vitro and in-vivo [34] . Plasmin activation can occur through either the release of endothelial t-PA or kallikrein-activated urokinase. The plasmin thus generated can then activate the ®rst factor in the complement cascade (C1) either directly or by the release of a-F XIIa, a product of F XII cleavage. These relations explain the lessened complement activation and the accordingly reduced in¯ammatory post-bypass syndrome that heparincoated ECC devices make possible [29, 35] .
Finally, though, the exact reaction pathways followed when blood comes in contact with the heparin-coated surfaces have yet to be de®nitively elucidated.
Coating techniques for extracorporeal devices
In the following section, the currently known techniques for surface-coatings or surface-treatments will be presented without value judgments. The information about the coating procedures originates with the manufacturer, when not otherwise noted by citations. At the beginning of the 1980s, Olle Larm and coworkers had developed a heparin-coating method for the Swedish company Carmeda. A short time later, Medtronic took on the license for extracorporeal circulation applications. The so-called`endpoint attachment 'achieved by a special covalent coupling mechanism allows a large part of the active heparin sequence to operate effectively in the bloodstream. This property attains a less thrombogenic surface on the one hand and decreases the denaturation of the adhered plasma proteins on the other hand [36] . Oxygenation systems with Carmeda heparin immobilization have been in clinical use for over a decade. Of the various coating systems, the CBAS w heparin-coating has been the best researched so far; numerous of experimental and clinical studies have been able to show the bene®ts of this coating ( Table 2 ). The lessened humoral and cellular activation [37±40], in particular the reduced complement activation [37,40±43] , deserve special attention. Recent clinical trials with 120 patients demonstrated shortened hospital stays, less drainage bleeding, and reduced cerebral complications with CBAS w compared to uncoated devices [44] . In addition, Bozdayi and coworkers found the production of oyxgen radicals was reduced by using this heparin-coat [45] . The diminished expression of the leukocyte adhesion molecule CD 11b/c in CBAS devices points to a decreased activation of neutrophils [46] . Comparative studies with other types of heparin-bondings have shown the high quality of this coating method [43,47±50] .Taken together, the use of CBAS coatings can reduce the in¯ammatory post-perfusion syndrome, and all of this coating technique's advantages are of particular relevance for long-term applications (ECMO).
Baxter (Dura¯o II
w ) The key to Dura¯o II w heparin-coating is an ionicallybound heparin-benzalkonium-chloride complex, which enables a relatively ®rm (for ionic bonds) connection with the foreign surface. Dura¯o II w has been in clinical use since 1988 after numerous in vitro, animal, and clinical trials tested its effectiveness (Table 1 ). Platelet protection [51] , reduced complement activation [29,52±54] , and more favorable post-operative lung function [55] are of particular note.
The newest and most comprehensive study of this material was recently published within the framework of a European multi-center study [56] with 805 patients undergoing aortocoronary bypass operations. With regard to blood loss, transfusion needs, intubation time, morbidity, mortality, and the length of the stay in intensive care, the study found no signi®cant differences between Dura¯o II w and uncoated systems. Nonetheless, for women and patients with aortic clamping times over 60 min, the use of Dura¯o II w decreased the need for blood products, intubation time, and the period of intensive care stay.
Jostra (BioLine Coating
w ) The coating method BioLine Coating w developed by the German company Jostra brings the high molecular weight heparin Liquemin w (Hoffman La-Roche, Basel, Switzerland) onto a base layer of immobilized polypeptides. This polypeptide adsorption can occur on hydrophilic as well as hydrophobic surfaces, whereby the creation of covalent bonds and ionic interactions between the heparin and the immobilized peptide achieves the stable coupling of the heparin molecule. The speci®c tie between the heparin molecule and the polypeptide preserves the active sequence of the heparin. BioLine Coating w , in clinical use since 1992, can be used to coat all components of the extracorporeal device including silicone parts.
The effectiveness of this heparin-coating could be proved pre-clinically in ex-vivo models and animal experiments [57±59]. Various clinical tests were also able to show BioLine Coating w 's positive in¯uence on the reaction mechanism triggered by contact activation. Another prospective randomized evaluation of 60 male patients who had to undergo an elective coronary operation clearly highlighted the advantages of the heparin-coated device during relatively short bypass times. In comparison to an uncoated perfusion system, the use of BioLine-Coating w demonstrated delayed contact activation and decreased alteration of leucocytes, as well as lessened coagulatory activity and improved platelet protection [60] . Moreover, studies of BioLine-Coating w perfusion devices used during surgical correction of congenital anomalies in infants and small children showed, in comparison to uncoated devices, a signi®cantly better platelet protection and lessened activation of the cytolytic complexes of the complement system [61] . In a very interesting study, Matheis and associates further revealed that BioLine-Coating w devices could reduce cerebral alterations resulting from extracorporeal circulation [62] .
In order to meet properly the demands of different application procedures and perfusion times, the Jostra Company offers two coatings: BioLine-Coating w (Extracorporeal Circulation ECC) for short perfusion times, especially in the area of heart surgery, and BioLine-Coating w (Long Term Perfusion LTP) for extracorporeal circulation of several days duration (ECMO, support systems, etc.)
New heparin-coatings

AOT (arti®cial organ technology) (AOThel
w ) The AOT company provides a heparin-coating named AOThel, which has found itself in clinical use since 1997. The system is a universally and from the structure itself hemocompatible coating procedure for tubing and oxygenation systems. The central feature is a heparin-coat with a certi®ed low molecular weight heparin. The AOThel procedure forsakes traditional substances for immobilizing heparin, such as polyamides and cationic tensides. Instead, the bond occurs comparable to the proteoglycan of the natural endothelium. All components of the extracorporeal device, including silicone, could be so coated, without altering their function or mechanical properties.
Corline Systems AB (Corline
The Swedish company Corline Systems AB, in cooperation with Rolf Larsson, a pioneer of heparin-coating technology, developed a new, simple, and easily reproducible technique for improving the hemocompatibility of glass, metal, and synthetic polymers [9, 63] . The Corline w heparin surface is produced by means of a uniform macromolecular heparin conjugate. This conjugate consists of multiple heparin molecules, which are covalently bound by speci®c linkers to an inert polyamine chain. After special pre-treatment, the conjugate binds itself to those surfaces of the medical device that come into contact with the blood. The speci®city of this covalent bond guarantees that the immobilized heparin's pentasaccharide sequence, important for its biological activity, is completely preserved.
The Corline w heparin-coat effects a minimal deposition and activation of both platelets and granulocytes (CB 11b), as well as a drastically reduced activation of the complement and coagulation systems. Corline w -coated internal coronary prostheses (stents) and ECC systems have now been in clinical since 1997.
3M
The newly developed heparin-coating procedure from the 3M company revolves around a technique for binding heparin covalently on polymer and metal surfaces. The method displays several parallels with the Carmeda coat: water soluble polyethylamine is bound to the surface to be coated, a layer of dextran-sulfate comes next, then another layer of polyethylamine, on which the oxidized heparin is ®nally, covalently bound by the addition of cyanoborohydride. The surface presented to the blood therefore consists of biologically active heparin.
All synthetic materials of the extracorporeal device, again, inclusive silicone, can be treated with this method. At the present time, though, this procedure ®nds itself still under preclinical evaluation, albeit awaiting clinical introduction in the very near future. Also just developed, this technique works with watersoluble synthetic polymers that are immobilized in two super®cial layers. The ®rst polymer layer serves as a primer and binds itself tightly to the arti®cial materials of the ECC device. The second layer, containing sulfonate groups, polyethylene-oxide chains, and heparin, is covalently bound to the primer and results in an insoluble surface coat. This surface in turn prevents the adhesion of blood cells and plasma proteins during contact with the blood.
The ®rst experiments with this technique indicated that the treated synthetic materials prevented the activation of the contact phase as well as platelet and leukocyte activation. The TBS coating intervened in the initial phases of the blood-material interactions and thereby prevented further activation at a very early stage in the cascade reaction. ECC systems with this coating are available since mid-1998.
Biocompatibles
Dennis Chapman has developed a method that provides an extremely interesting alternative to coating surfaces with anticoagulants: employing phospholipids from natural membranes as a coating substance. Zwaal and coworkers [64] had already proved in 1977 that, in contrast to their exterior surfaces, the interior surfaces of erythrocyte membranes possess strong thrombogenic properties. Further examination showed an asymmetrical distribution of the phospholipids over the cell membrane, with phosphorylcholine-containing lipids dominating in the outer membrane of the bilayer [65] (Fig. 2) .
Chapman's group succeeded in coupling synthetic methacryloyl-phosphorylcholine/lauryl-methacrylate copolymers to metal and synthetic surfaces. The term`biomembrane mimicry' accordingly arose for phosphorylcholine-coated foreign surfaces [66] .
In vitro experiments and animal tests have shown that phosphorylcholine-coated arti®cial polymers possess outstanding thrombogenic resistance and display only minimal adhesion of plasma proteins and platelets [67, 68] . Until now, this coating technique has only been offered for contact lenses, although it should be soon ready for the market of extracorporeal circulation devices.
Cobe (SMAR x Te)
This coating procedure, applicable to all surfaces of the ECC systems, is not a coating technique in the usual sense. Rather, it is a surface modifying additive (SMA), which is contributed to the initial synthetic materials in the device's production phase. The copolymer distributes itself in the synthetic materials during the polymerization process and due to its charge characteristics, moves to the surface of the basis material as it cools. Thus, a new surface of 100% SMA forms. The surface's microscopic structure of alternating hydrophilic and hydrophobic regions carries a net neutral charge, thereby reducing platelet and leukocyte deposition. Tsai and others [69] could prove that SMA surfaces decreased coagulation activation and signi®cantly reduced contact phase and complement activation. Gu et al. [70] found a better platelet protection in clinical CPB by using SMA treated devices. Such SMA surfaces in extracorporeal devices have undergone evaluative testing in select centers since 1996 and have been available since mid-1997.
Possible contraindication for heparin-coated devices
Heparin-coated surfaces are, in principal, universally applicable without concern. Only one potentially troublesome area exists at this time: the ventricular assist devices (VAD). These devices are increasingly employed for therapy-refractory pump failure or as`bridging to transplant' endeavors. On account of their material properties, all these assist devices reveal a more or less pronounced bioincompatibility, and thus their use can be associated with subsequently heightened bleeding complications or thromboembolic events. Most cardiac centers attempt to minimize both the thrombogenicity and systemic heparin dose by using heparin-coated VADs. Yet a reduction of their hemocompatibility cannot be completely excluded for the following reason: after the implantation of the VAD, the anticoagulant that was necessary during the ECC now needs to be neutralized, normally by its antidote protamine. However, unbound protamine could come into contact with the heparin-coating of the VAD and accordingly neutralize it, and its hemocompatible characteristics, as well [71, 72] .
A recently-presented study examined the in¯uence of protamine application on the hemocompatibility of heparin-coatings in an in-vitro`closed loop' model. Judging from the measured coagulation and in¯ammation markers, the protamine contact had signi®cantly worsened the hemocompatibility of the heparin-coated surface. In light of these results, especial caution should be given to protamine application and the anticoagulation status during the clinical use of VADs with heparin-coatings, so as to minimize thromboembolic complications. In future it would be even better to eliminate the high systemic heparin concentrations by extracorporeal heparin removal devices [73] .
Conclusion and future prospects
In spite of all the technical improvements made to improve the hemocompatibility of ECC components, a noticeable activation of plasma proteins and corpuscular blood components still transpires. The long-range goal remains the creation of an optimally hemocompatible surface (endothelium-like), which the blood would no longer recognize as unphysiological and hence would not induce humoral and cellular defenses as well as rejection mechanisms against it.
In summary, however, with the results of numerous studies on the hemocompatibility of extracorporeal circulation in hand, one can de®nitely work from the assumption that heparin-coated devices retard the activation of cellular and humoral mechanisms. Above all, the reduction of a general in¯ammatory response initiated by the extracorporeal circulation represents an important application for heparin-coated devices.
Above and beyond the long-term applications, routine heart operations have also markedly begun to utilize heparin-coated devices. This trend will assuredly continue in the coming years and is an important step toward higher hemocompatibility of blood-contacting surfaces in the ECC device.
Heparin-coatings are merely the beginning of improved hemocompatibility for all materials that come into contact with human blood or tissues. Intelligent materials with almost completely physiological surfaces will be at the surgeon's disposal within the next few years. Such materials will be able to mimic endothelial functions and respond to individual changes in the patient's status with the controlled release of adequate pharmacological substances.
